GRT3983Y

GRT3983Y is an **investigational centrally acting analgesic** that was developed by Grünenthal for the treatment of **painful diabetic peripheral neuropathy**. It was evaluated in a multicenter, randomized, double-blind, placebo-controlled, Phase 2 clinical trial, in which oral overencapsulated tablets were administered at doses of 100-300 mg/day for up to 16 weeks. The mechanism of action is not publicly disclosed, but it is referred to in sources as a **centrally acting analgesic** rather than a peripheral acting or typical nonsteroidal agent. The development program was terminated in Phase 2, and no efficacy data have been released, only adverse event recordings[1][3][5].